Compare Stocks: IMMP, IRON, BEAM, and CLDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$25.67 +4.8%	$26.68	$20.23 ▼ $38.26	$2.53B	2.2	1.98 million shs	2.00 million shs
CLDX Celldex Therapeutics	$32.59 +3.0%	$38.32	$22.10 ▼ $45.14	$2.49B	0.9	2.08 million shs	1.26 million shs
IMMP Prima BioMed	$4.27 -1.8%	$6.89	$4.16 ▼ $70.60	$32.05M	2.27	27,317 shs	25,190 shs
IRON Disc Medicine	$63.33 -1.8%	$74.76	$40.00 ▼ $99.50	$2.48B	0.93	569,949 shs	456,319 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	+0.95%	-17.40%	-30.63%	-4.85%
CLDX Celldex Therapeutics	0.00%	+1.77%	-20.24%	-16.60%	+19.84%
IMMP Prima BioMed	0.00%	-17.46%	-40.39%	-50.84%	-88.31%
IRON Disc Medicine	0.00%	-1.12%	-18.58%	-16.23%	-4.82%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$25.67 +4.8%	$26.68	$20.23 ▼ $38.26	$2.53B	2.2	1.98 million shs	2.00 million shs
CLDX Celldex Therapeutics	$32.59 +3.0%	$38.32	$22.10 ▼ $45.14	$2.49B	0.9	2.08 million shs	1.26 million shs
IMMP Prima BioMed	$4.27 -1.8%	$6.89	$4.16 ▼ $70.60	$32.05M	2.27	27,317 shs	25,190 shs
IRON Disc Medicine	$63.33 -1.8%	$74.76	$40.00 ▼ $99.50	$2.48B	0.93	569,949 shs	456,319 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	0.00%	+0.95%	-17.40%	-30.63%	-4.85%
CLDX Celldex Therapeutics	0.00%	+1.77%	-20.24%	-16.60%	+19.84%
IMMP Prima BioMed	0.00%	-17.46%	-40.39%	-50.84%	-88.31%
IRON Disc Medicine	0.00%	-1.12%	-18.58%	-16.23%	-4.82%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	2.79	Moderate Buy	$49.00	90.88% Upside
CLDX Celldex Therapeutics	2.86	Moderate Buy	$61.92	90.01% Upside
IMMP Prima BioMed	2.40	Hold	$110.00	2,476.11% Upside
IRON Disc Medicine	2.77	Moderate Buy	$110.18	73.98% Upside

Current Analyst Ratings Breakdown

Latest IMMP, IRON, BEAM, and CLDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$64.00
9/23/2026	BEAM Beam Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/23/2026	CLDX Celldex Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$70.00 ➝ $88.00
9/23/2026	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$50.00 ➝ $57.00
9/22/2026	CLDX Celldex Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$68.00
9/22/2026	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $64.00
9/22/2026	CLDX Celldex Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$61.00 ➝ $72.00
9/16/2026	IRON Disc Medicine	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$79.00 ➝ $86.00
9/14/2026	IMMP Prima BioMed	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
9/10/2026	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
9/10/2026	IRON Disc Medicine	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$139.74M	18.97	N/A	N/A	$12.20 per share	2.10
CLDX Celldex Therapeutics	$1.54M	1,661.88	N/A	N/A	$7.93 per share	4.11
IMMP Prima BioMed	$16.40M	1.92	N/A	N/A	$5.67 per share	0.75
IRON Disc Medicine	N/A	N/A	N/A	N/A	$19.52 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
CLDX Celldex Therapeutics	-$258.76M	-$4.35	N/A	N/A	N/A	N/A	-52.35%	-47.61%	11/9/2026 (Estimated)
IMMP Prima BioMed	-$53.82M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	-$212.18M	-$6.58	N/A	N/A	N/A	N/A	-37.17%	-33.65%	11/5/2026 (Estimated)

Latest IMMP, IRON, BEAM, and CLDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million
7/30/2026	Q4 2026	IMMP Prima BioMed	N/A	-$1.80	N/A	-$0.0850	N/A	$3.68 million
7/30/2026	Q2 2026	IRON Disc Medicine	-$1.71	-$1.54	+$0.17	-$1.54	$1.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	0.09	14.57	14.57
CLDX Celldex Therapeutics	N/A	11.82	11.82
IMMP Prima BioMed	N/A	5.69	N/A
IRON Disc Medicine	0.09	24.14	24.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CLDX Celldex Therapeutics	N/A
IMMP Prima BioMed	2.32%
IRON Disc Medicine	83.70%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.80%
CLDX Celldex Therapeutics	5.20%
IMMP Prima BioMed	3.07%
IRON Disc Medicine	3.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	540	103.29 million	99.36 million	Optionable
CLDX Celldex Therapeutics	198	78.53 million	74.45 million	Optionable
IMMP Prima BioMed	2,021	7.37 million	7.14 million	Optionable
IRON Disc Medicine	165	38.39 million	36.95 million	Not Optionable

IMMP, IRON, BEAM, and CLDX Headlines

Recent News About These Companies

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

2 hours ago | globenewswire.com

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

October 4 at 11:16 PM | newsfilecorp.comN

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

October 3 at 10:00 PM | newsfilecorp.comN

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

October 2 at 3:55 PM | prnewswire.com

ROSEN, A LEADING NATIONAL FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

September 30, 2026 | newsfilecorp.comN

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

September 29, 2026 | newsfilecorp.comN

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

September 28, 2026 | globenewswire.com

ROSEN, A LONGSTANDING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

September 27, 2026 | markets.businessinsider.com

ROSEN, A LONGSTANDING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

September 27, 2026 | newsfilecorp.comN

Bank of America Corp DE Makes New $9.88 Million Investment in Disc Medicine, Inc. $IRON

September 27, 2026 | marketbeat.com

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

September 26, 2026 | prnewswire.com

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

September 25, 2026 | globenewswire.com

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

September 24, 2026 | newsfilecorp.comN

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

September 23, 2026 | newsfilecorp.comN

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

September 22, 2026 | globenewswire.com

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

September 21, 2026 | prnewswire.com

Disc Medicine, Inc. (NASDAQ:IRON) Receives Average Recommendation of "Moderate Buy" from Analysts

September 21, 2026 | marketbeat.com

Rosen Law Firm Encourages Disc Medicine, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - IRON

September 16, 2026 | prnewswire.com

Kevin Bitterman Sells 27,136 Shares of Disc Medicine (NASDAQ:IRON) Stock

September 15, 2026 | marketbeat.com

Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

September 15, 2026 | globenewswire.com

Disc Medicine, Inc. (IRON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IMMP, IRON, BEAM, and CLDX Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$25.67 +1.17 (+4.78%)

Closing price 04:00 PM Eastern

Extended Trading

$25.50 -0.17 (-0.64%)

As of 07:59 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Celldex Therapeutics NASDAQ:CLDX

$32.59 +0.94 (+2.97%)

Closing price 04:00 PM Eastern

Extended Trading

$32.32 -0.27 (-0.83%)

As of 07:42 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Prima BioMed NASDAQ:IMMP

$4.27 -0.08 (-1.84%)

Closing price 03:58 PM Eastern

Extended Trading

$4.23 -0.04 (-0.94%)

As of 07:30 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Disc Medicine NASDAQ:IRON

$63.33 -1.18 (-1.83%)

Closing price 04:00 PM Eastern

Extended Trading

$63.36 +0.02 (+0.04%)

As of 07:30 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMMP, IRON, BEAM, and CLDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMMP, IRON, BEAM, and CLDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMMP, IRON, BEAM, and CLDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMMP, IRON, BEAM, and CLDX Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Celldex Therapeutics NASDAQ:CLDX

Prima BioMed NASDAQ:IMMP

Disc Medicine NASDAQ:IRON

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMMP, IRON, BEAM, and CLDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMMP, IRON, BEAM, and CLDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMMP, IRON, BEAM, and CLDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMMP, IRON, BEAM, and CLDX Company Descriptions

Beam Therapeutics NASDAQ:BEAM

Celldex Therapeutics NASDAQ:CLDX

Prima BioMed NASDAQ:IMMP

Disc Medicine NASDAQ:IRON

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools